Table 1.

Baseline and follow-up information

Era 1Era 2Era 3P (post hoc)
n8614549
Clinical presentation
    female gender (%)413032>0.1
    age (years)44 ± 1549 ± 1453 ± 160.01 (1 < 2,3)
    CrCl (ml/min per 1.73 m2)83 ± 3174 ± 2683 ± 330.03 (2 < 1,3)
    proteinuria
        initial (g/d)5.3 (3.7 to 9.0)6.2 (3.5 to 10.4)6.6 (3.2 to 10.0)>0.1
        peak (g/d)7.8 (4.4 to 11.4)10.2 (6.0 to 17.4)10.0 (5.9 to 14.9)<0.01 (1 < 2,3)
    MAP (mmHg)101 ± 15102 ± 1299 ± 13>0.1
    number of antihypertensive medications0 (0 to 1)0 (0 to 1)0 (0 to 1)>0.1
Length of follow-up (months)58 (38 to 83)38 (21 to 57)51 (26 to 66)<0.01 (1 > 2,3)
Therapy during follow-up
    number of antihypertensive medications0.3 (0.0 to 0.6)0.4 (0.0 to 1.0)1.0 (0.7 to 1.5)<0.01 (1,2 < 3)
    RAS blockade (%)02790<0.01 (1 < 2<3)
        duration (% of patient follow-up)32 (8 to 62)76 (47 to 96)<0.01
    immunosuppressive therapy
        none (%)5546390.02 (1 < 2,3)
        not currently recommended (%)383126
        currently recommended (%)72335
Clinical follow-up
    MAP (mmHg)101 ± 10100 ± 995 ± 80.02 (1,2 > 3)
    proteinuria
        change from peak to last (g/d)−4.6 (−8.6 to −2.2)−6.4 (−11.0 to −2.7)−5.3 (−12.7 to −2.4)0.06
        no remission (%)2437180.02 (2 > 1,3)
    slope (ml/min per 1.73 m2 per year)−2.8 ± 6.7−5.0 ± 10.3−2.6 ± 6.00.08
    renal survivalSee Figure 2
  • Values are expressed as mean ± SD or median (interquartile range). CrCl, creatinine clearance; MAP, mean arterial pressure; RAS, renin-angiotensin system.